Anebulo Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.anebulo.com
- Introduction
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
Observational Study of THC Concentrations in Acute Cannabinoid Intoxication
Recruiting
- Conditions
- Acute Cannabinoid Intoxication
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT06017622
- Locations
- 🇺🇸
Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, United States
🇺🇸University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT05282797
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, ZH, Netherlands
© Copyright 2025. All Rights Reserved by MedPath